Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's Lymphoma

• Status: Unknown status
• Trial end date: 1969-12-31

Summary

The purpose of this study is to enable retreatment with Iodine-131 Anti-B1 Antibody therapy for patients with non-Hodgkin's lymphoma (NHL) who previously responded (PR, CCR, or CR) for at least 3 months to Iodine-131 Anti-B1 Antibody therapy.

• Phase: N/A

Details

• Lead Sponsor: Corixa Corporation
• Collaborator: GlaxoSmithKline
• Treatments: Antibodies; Antibodies, Monoclonal; Cadexomer iodine; Immunoglobulins; Iodine; Iodine-131 anti-B1 antibody; Tositumomab I-131